Latest CSL News

The week was split between big earnings reactions and small-cap rocks-and-rigs rallies. Pro Medicus sank despite record numbers, while a handful of explorers jumped on fresh discoveries and policy wins.

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

CSL Limited has released its half-year results showing a slight revenue decline amid ongoing transformation efforts, while maintaining its full-year guidance and expanding its share buyback program.

CSL Limited has announced an ordinary dividend of USD 1.30 per share for the six months ending December 2025, payable in April 2026 with multi-currency options for shareholders.

CSL Limited reported a 7% decline in underlying NPATA to US$1.9 billion for the half-year, weighed down by restructuring costs and impairments, yet maintains full-year guidance and expands its share buy-back program.

CSL Limited reported a sharp 80% drop in net profit for the half year ended December 2025, driven by significant restructuring and impairment charges, yet maintained its growth guidance and dividend payout.

CSL Limited announces the retirement of CEO Dr Paul McKenzie, with veteran executive Gordon Naylor appointed as interim CEO and Managing Director. The leadership change marks a new chapter for the biotech giant amid ongoing strategic transformation.

CSL Limited’s latest Capital Markets Day presentation highlights CSL Seqirus’s strategic positioning to capitalize on a recovering US influenza vaccine market and global growth opportunities.

CSL Limited has revised its financial outlook for FY26, citing lower US influenza vaccination rates and government cost controls in China, while postponing the planned demerger of its Seqirus vaccine business and announcing a major cost-saving program.

CSL Limited has partnered with Dutch biotech VarmX to develop VMX-C001, a novel treatment aimed at reversing bleeding in patients on FXa inhibitors, with FDA Fast Track status and a potential 2029 launch.

CSL Limited has updated its dividend announcement for the first half of FY2025, confirming a USD 1.62 per share ordinary dividend and clarifying currency payment arrangements for global shareholders.

CSL Limited reported solid FY25 financials with 5% revenue growth and announced a strategic transformation including a $500 million annual cost saving target and plans to spin off its vaccine business, CSL Seqirus, as a separate ASX-listed entity.